Ginkgo Bioworks Holdings, Inc. (DNA) Stock

Ginkgo Bioworks Holdings, Inc. (DNA) is a Healthcare stock trading at $9.16 (as of 2026-06-18), with a market capitalization of $577.76M and a trailing P/E of -1.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Ginkgo Bioworks Holdings, Inc. develops a platform for programming cells to support biological production of products such as therapeutics, food ingredients, and chemical compounds. The company serves multiple end markets including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals, and it has a partnership with Selecta Biosciences on the ImmTOR technology platform.

Valuation — source: SEC EDGAR (first-party)
Price	$9.16
Market Cap	$577.76M
P/E Ratio	-1.4
EV / EBITDA	-1.2
Price / Book	1.10
Price / Sales	3.44
DCF Value (model)	$-48.62
DCF Upside vs Price	-630.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$170.16M
Net Margin	-183.8%
Return on Equity	-68.7%
Current Ratio	5.15
Revenue Growth (YoY)	-59.7%
EPS Growth (YoY)	-17.3%
FCF Growth (YoY)	-17.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	-7.54 (distress)

Valuation vs Sector & Industry
Stock P/E	-1.4
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-106.7%
vs Industry	-108.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	METEORA CAPITAL, LLC ($183.65M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Jason Kelly
Employees	834
Country	US
IPO Date	2021-04-19

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.